Articles tagged with Antiparasitic Agents
The European Medicines Agency has granted a positive opinion to Acoziborole Winthrop as a single-dose oral treatment for both early- and advanced-stage gambiense sleeping sickness in adults and adolescents. The medicine, co-developed by DNDi and Sanofi, could provide a significant advance over current therapies.
New research reveals that the immune system has a potent weapon against the brain parasite Toxoplasma gondii: an enzyme called caspase-8. This discovery offers new insights into how our bodies control the parasite and may lead to better treatments for patients with compromised immune systems.
The winners of the Applied Microbiology International Horizon Awards 2025 have been recognized for their groundbreaking contributions to global challenges through applied microbiology. The awards celebrate excellence across various domains, including drug discovery and sustainable agriculture.
Researchers have discovered that the same beneficial bacteria occur in pollen stores of honeybee colonies and on nearby plants, producing compounds that kill pathogens of bees and plants. These endophytes can be used to develop new treatments for crops and hives.
A study published in PLOS Neglected Tropical Diseases has shown that combining country-level information with individual-level variables can improve the identification of soil-transmitted helminth infections among migrant populations. Researchers found that country-level indicators are stronger predictors than individual-level variable...
Researchers at Okinawa Institute of Science and Technology have successfully treated a newly discovered parasitic copepod species that was killing squid eggs. The eco-friendly treatment uses peracetic acid to kill the parasites in under two minutes, with zero effect on squids or their generations.
Researchers at Scripps Research have found a way to modify picrotoxinin, a plant-derived toxin, with improved properties, making it easier to synthesize and modify. The modified version, 5Me-picrotoxinin, shows better chemical stability and is safer for humans.
A new review paper aims to educate medical professionals on diagnosing and treating rat lungworm disease, which is expected to spread globally due to climate change. Early diagnosis and treatment are critical in reducing the risk of complications such as long-term disability.
A study by North Carolina State University found that two common veterinary drugs, Fluralaner and Ivermectin, are effective in killing bed bugs on poultry farms. Fluralaner was highly effective against bed bugs with resistance to common insecticides.
A new antiparasitic compound has shown 100% efficacy in eliminating T. cruzi, the parasite that causes Chagas disease, in mice and non-human primates. The treatment could provide a safer alternative to current medications with significant side effects and variable efficacy.
A mass drug administration (MDA) program with ivermectin is being delivered on a mass scale in the Solomon Islands, a world first. The program aims to prevent scabies, a contagious and itchy skin condition that affects a third of the nation's children.
A new study found that one dose of ivermectin was just as effective as two doses in reducing scabies prevalence and impetigo cases. The 'screen-and-treat' approach using permethrin cream was also effective, but impractical for large-scale implementation.
Researchers developed nanoscale insecticidal hair coating for prolonged anti-lice protection, reducing re-treatments and side effects. The coating, formed using halloysite nanotubes, retains its protective properties after washing the animal's hair.
Monash University researchers have identified an anti-parasitic drug, Ivermectin, as a potential treatment for COVID-19. The study found that a single dose of the drug can stop the SARS-CoV-2 virus from growing in cell culture within 48 hours.
A two-year update of a comparative trial on mass drug administration against scabies shows the infection rate remains significantly low, with a 89% decline in prevalence. The treatment used ivermectin, an oral anti-parasitic drug, and its effect was found to be long-lasting.
A team of researchers has developed a novel pharmaceutical formulation to administer triclabendazole, an anti-parasitic drug used to treat flatworm infections. The new nanocapsule formulation produces capsules less than one micron in size and is 100 times more soluble than its current tablet form.
Researchers at the University of Iowa used a multidisciplinary approach to identify 90 FDA-approved drugs that may have potential as anti-seizure treatments. Gene expression profiling and bioinformatics revealed that these drugs significantly reduced seizures in zebrafish models.
A CWRU-led study shows a single dose of the new triple-drug therapy is significantly more effective at killing microscopic larval worms in people diagnosed with lymphatic filariasis. This finding has led to changes in WHO treatment guidelines, offering promise for eliminating this disease from global health threats.
A new study found that substandard and falsified medicines are a serious problem in much of the world. In low- and middle-income countries, over 13% of essential medicines are substandard or falsified, with antimalarials and antibiotics being the most commonly affected.
A new ecotoxicological field test was successfully conducted to verify the toxicity of livestock medications, finding that earthworms can compensate for the loss of other organisms. The study provides important insights into minimizing the risks of drug residues in nature.
A promising discovery has been made in treating and preventing human parainfluenza virus, the second most prevalent cause of acute respiratory tract infection in infants. Researchers have found that combining two existing drugs, Suramin and Relenza, can effectively block the infection.
The Liverpool School of Tropical Medicine has received £10m to support programmes reducing LF prevalence and eliminating the disease. Over a billion people are at risk, with 40 million already infected.
The study confirms voriconazole's effectiveness in combating a wide range of fungal infections, including those caused by Candida species. It is also noted that voriconazole exhibits higher potency and spectrum activity compared to itraconazole against yeast species.